GH / Guardant Health, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925

Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25% PALO ALTO, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2025 GUARDANT HEALTH, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2025 GUARDANT HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization

Second Amendment to Lease, dated March 6, 2019 by and between Registrant and Metropolitan Life Insurance Company

signed595pen101sagleases SECOND AMENDMENT TO LEASE This Second Amendment to Lease ("Amendment") is entered into, and dated for reference purposes, as of f\'ll-cc.

Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890

Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% PALO ALTO, Calif.

Third Amendment to Lease, dated April 3, 2025 by and between Registrant and Metropolitan Life Insurance Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒     Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  ☒      Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.

As filed with the Securities and Exchange Commission on February 24, 2025

As filed with the Securities and Exchange Commission on February 24, 2025 Registration No.

018 Incentive Award Plan Annual Cash Incentive Program

Exhibit 10.22 Guardant Health, Inc. 2018 Incentive Award Plan Annual Cash Incentive Program Updated as of January 1, 2025 Overview This Annual Cash Incentive Program (the “Bonus Plan”) is adopted under Section 7(a) of the Guardant Health, Inc. (the “Company” or “Guardant Health”) 2018 Incentive Award Plan (the “Plan”) and is intended to recognize, reward and retain Participants (as defined below)

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects full year 2025 total revenue to be in the range of $850 to $860 million PALO ALTO, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

nsider Trading Compliance Policy

Exhibit 19.1 GUARDANT HEALTH, INC. INSIDER TRADING COMPLIANCE POLICY As in effect October 23, 2024 CONTENTS I. SUMMARY 2 II. STATEMENT OF POLICIES PROHIBITING INSIDER TRADING 2 III. EXPLANATION OF INSIDER TRADING 3 IV. STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING 5 V. ADDITIONAL RESTRICTIONS AND GUIDANCE 8 VI. RULE 10b5-1 TRADING PLANS AND SECTION 16 9 VII. EXECUTION AND RETURN OF CERTIFICAT

List of Subsidiaries

Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington Morpheus Merger Sub, Inc. Delaware Guardant Health Screening Corp. Delaware Guardant Health International, Inc. Delaware Guarda

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Indenture, dated as of February 14, 2025, between Guardant Health, Inc. and U.S. Bank Trust Company, National Association, as Trustee

Exhibit 4.1 GUARDANT HEALTH, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of February 14, 2025 1.25% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction. 1 Section 1.01. Definitions. 1 Section 1.02. Other Definitions. 12 Section 1.03. Rules of Construction. 13 Article 2. The Notes. 14 Section 2.01. Form, Dat

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

JOINT FILING AGREEMENT

JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Guardant Health, Inc.

Form of Exchange Agreement

Exhibit 10.1 February 6, 2025 Guardant Health, Inc. 3100 Hanover Street Palo Alto, California 94304 Attention: Chief Financial Officer Re: Exchange and/or Subscription for Guardant Health, Inc. Convertible Senior Notes due 2031 Ladies and Gentlemen: Guardant Health, Inc., a Delaware corporation, (the “Company”), is offering a new series of its Convertible Senior Notes due 2031 (the “New Notes”). T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2025 GUARDANT HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

Guardant Health Announces Debt Exchange Transactions

EX-99.1 Exhibit 99.1 Guardant Health Announces Debt Exchange Transactions PALO ALTO, Calif. February 7, 2025 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its outstanding 0% Convertible Senior Notes due 2027 (the “2027

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

Exhibit 99.1 Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results Full year revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif. January 13, 2025 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended Dece

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

GH / Guardant Health, Inc. / CADIAN CAPITAL MANAGEMENT, LP Passive Investment

SC 13G 1 formsc13g-guardant.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 40131M109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap

GH / Guardant Health, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S

JOINT FILING AGREEMENT

JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Guardant Health, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920 PALO ALTO, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2024 GUARDANT HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

Roberto A. Mignone Joins Guardant Health Board of Directors

Exhibit 99.1 FOR IMMEDIATE RELEASE Roberto A. Mignone Joins Guardant Health Board of Directors PALO ALTO, Calif.- (October 24, 2024) - Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment man

GH / Guardant Health, Inc. / Deep Track Capital, LP Passive Investment

SC 13G 1 deeptrack-gh100224.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health Inc. (Name of Issuer) Common Stock, $0.00001 Par Value (Title of Class of Securities) 40131M109 (CUSIP Number) October 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

GH / Guardant Health, Inc. / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2024 GUARDANT HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizatio

by and between the Company and Jefferies LLC, dated August 23, 2024

Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 23, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Guardant Health, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common st

Up to $400,000,000 Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 PROSPECTUS SUPPLEMENT (to Prospectus Dated May 22, 2023) Up to $400,000,000 Common Stock We have entered into an open market sale agreementSM (the “Sales Agreement”), dated August 23, 2024, with Jefferies LLC (“Jefferies”), relating to the offer and sale of shares of our common stock, par value $0.00001 per share (our “

Calculation of Filing Fee Tables (Form Type) Guardant Health, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Guardant Health, Inc.

Form of Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan

Exhibit 10.3 Founder RSU Agreement GUARDANT HEALTH, INC. 2018 INCENTIVE AWARD PLAN GLOBAL RESTRICTED STOCK UNIT GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Global Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and cond

Form of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan

Exhibit 10.4 Founder PSU Agreement GUARDANT HEALTH, INC. 2018 INCENTIVE AWARD PLAN GLOBAL PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Performance-Based Restricted Stock Units (the “PSUs”) described in this Global Performance-Based Restricted Stock Unit Grant Notic

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approved by FDA as primary option for CRC scre

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approved by FDA as primary option for CRC screening and is commercially available in U.

Form of Stock Option Grant Notice and Restricted Stock Unit Grant Notice under the 2023 Employment Inducement Incentive Award Plan

Exhibit 10.5 GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Stock Option Grant Notice (the “Grant Notice”) subject to the terms and conditions of the 2023 Employment Inducement In

Amended and Restated Executive Severance Plan

Exhibit 10.1 GUARDANT HEALTH, INC. EXECUTIVE SEVERANCE PLAN As amended and restated on April 22, 2024 Guardant Health, Inc., a Delaware corporation, (the “Company”) has adopted this Executive Severance Plan, including the attached Exhibits (the “Plan”), for the benefit of Participants (as defined below) on the terms and conditions hereinafter stated. The Plan, as initially adopted on September 15,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Form of Stock Option Agreement under the 2018 Incentive Award Plan

Exhibit 10.2 GUARDANT HEALTH, INC. 2018 INCENTIVE AWARD PLAN GLOBAL STOCK OPTION GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Global Stock Option Grant Notice (the “Grant Notice”) subject to the terms and conditions of the 2018 Incentive Award Plan, as may be

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization

Guardant Health’s Shield

EX-99.1 Exhibit 99.1 NEWS RELEASE Guardant Health’s ShieldTM blood test approved by FDA as a primary screening option, clearing path for Medicare reimbursement and a new era of colorectal cancer screening • Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage • Blood test offers easy, convenient

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2024 GUARDANT HEALTH, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

Exhibit 99.1 FOR IMMEDIATE RELEASE Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors PALO ALTO, Calif.—(July 18, 2024)— Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Onc

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2024 GUARDANT HEALTH, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2024 GUARDANT HEALTH, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Exhibit 99.1 NEWS RELEASE FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option May 23, 2024 • The advisory committee offers valuable non-binding recommendations for the FDA • Blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2024 GUARDANT HEALTH, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds

Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  ☒      Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒     Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

GH / Guardant Health, Inc. / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Form of Letter Agreement

Exhibit 10.1 March 18, 2024 Re: Compensation Arrangement Dear [Helmy / AmirAli]: This letter serves to memorialize your agreement with Guardant Health, Inc. (the “Company”) regarding certain compensation-related matters and amends and restates the prior letter by and between you and the Company, dated May 26, 2020 (the “Prior Letter”). Capitalized terms used but not otherwise defined herein shall

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization

As filed with the Securities and Exchange Commission on February 23, 2024

As filed with the Securities and Exchange Commission on February 23, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

List of Subsidiaries

Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington Morpheus Merger Sub, Inc. Delaware Guardant Health Screening Corp. Delaware Guardant Health International, Inc. Delaware Guarda

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 22, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Policy for Recovery of Erroneously Awarded Compensation

GUARDANT HEALTH, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Guardant Health, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Policy

Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 milli

Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 million PALO ALTO, Calif.

GH / Guardant Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Guardant Health Inc Title of Class of Securities: Common Stock CUSIP Number: 40131M109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒

GH / Guardant Health, Inc. / Capital International Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2024 GUARDANT HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results Full year revenue growth of 25% driven by clinical volume growth of 39%

Exhibit 99.1 Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results Full year revenue growth of 25% driven by clinical volume growth of 39% PALO ALTO, Calif. January 8, 2024 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2023. Full year 2023 prelimin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 GUARDANT HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizatio

Common Stock Purchase Agreement, dated December 20, 2023, between Guardant Health, Inc. and Baillie Gifford Overseas Limited, acting as agent and representative for and on behalf of the investors set forth therein

Exhibit 10.1 GUARDANT HEALTH, INC. COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of December 20, 2023, by and between Guardant Health, Inc., a Delaware corporation (“Guardant”), and Baillie Gifford Overseas Limited, acting as agent and representative for and on behalf of the investors set forth in Exhibit A hereto (the “Investors”). WHERE

Calculation of Filing Fee Tables (Form Type) GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) GUARDANT HEALTH, INC.

3,387,446 Shares of Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 PROSPECTUS SUPPLEMENT (to Prospectus Dated May 22, 2023) 3,387,446 Shares of Common Stock We are offering 3,387,446 shares of our common stock, par value $0.00001 per share, at an offering price of $26.77 per share directly to certain investors pursuant to this prospectus supplement, the accompanying prospectus an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2023 GUARDANT HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford

Exhibit 99.1 Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford PALO ALTO, Calif. Dec 21, 2023 (BUSINESS WIRE) — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its co

Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test

Exhibit 99.1 Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test PALO ALTO, Calif. Dec 19, 2023 (BUSINESS WIRE) — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to rev

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 19, 2023 GUARDANT HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 19, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Guardant Health to Appeal Federal District Court Verdict

EX-99.1 Exhibit 99.1 PRESS RELEASE Guardant Health to Appeal Federal District Court Verdict PALO ALTO, Calif. - (BUSINESS WIRE) - (November 15, 2023) – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guard

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

2023 Employment Inducement Award Plan, as approved on August 2, 2023

GUARDANT HEALTH, INC. 2023 Employment Inducement Incentive Award Plan (Effective as of August 2, 2023) 1.Purpose. The Plan’s purpose is to enhance the Company’s ability to attract and retain Eligible Individuals who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Sectio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance Q3 revenue increased 22% year over year driven by clinical volume growth of 35% Raises 2023 revenue guidance to $553 to 556 million

Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance Q3 revenue increased 22% year over year driven by clinical volume growth of 35% Raises 2023 revenue guidance to $553 to 556 million PALO ALTO, Calif.

Form of Stock Option Grant Notice and Restricted Stock Unit Grant Notice under the 2023 Employment Inducement Incentive Award Plan

GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Stock Option Grant Notice (the “Grant Notice”), subject to the terms and conditions of the 2023 Employment Inducement Incentive Awar

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 GUARDANT HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Form of Restricted Stock Unit Award Grant Notice under the 2023 Employment Inducement Incentive Award Plan

EX-99.1c Exhibit 99.1(c) GUARDANT HEALTH, INC. FORM OF RESTRICTED STOCK UNIT AWARD GRANT NOTICE UNDER THE 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN [ATTACHED] * * * * * GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant

2023 Employment Inducement Incentive Award Plan

EX-99.1a Exhibit 99.1(a) GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN [ATTACHED] * * * * * GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN 1. Purpose. The Plan’s purpose is to enhance the Company’s ability to attract and retain Eligible Individuals who are expected to make important contributions to the Company by providing these individuals with equi

As filed with the Securities and Exchange Commission on August 10, 2023

S-8 As filed with the Securities and Exchange Commission on August 10, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.

Form of Stock Option Grant Notice and Stock Option Agreement under the 2023 Employment Inducement Incentive Award Plan

Exhibit 99.1(b) GUARDANT HEALTH, INC. FORM OF STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT UNDER THE 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN [ATTACHED] * * * * * GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the

Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million

Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million PALO ALTO, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2023 GUARDANT HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Executive Severance Plan

Exhibit 10.1 GUARDANT HEALTH, INC. EXECUTIVE SEVERANCE PLAN As amended and restated on May 2, 2023 Guardant Health, Inc., a Delaware corporation, (the “Company”) has adopted this Executive Severance Plan, including the attached Exhibits (the “Plan”), for the benefit of Participants (as defined below) on the terms and conditions hereinafter stated. The Plan, as initially adopted on September 15, 20

Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research

EX-99.1 Exhibit 99.1 PRESS RELEASE Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research PALO ALTO, CALIF., August 1, 2023 /BUSINESSWIRE/ – Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, today announced an agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequenci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2023 GUARDANT HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 GUARDANT HEALTH, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Underwriting Agreement, dated as of May 22, 2023, among Guardant Health, Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and SVB Securities LLC, as representatives of the several underwriters named therein.

U.S. Securities and Exchange Commission You’ve Exceeded the SEC’s Traffic Limit Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation) (Commission File

12,500,000 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 PROSPECTUS SUPPLEMENT (to Prospectus Dated May 22, 2023) 12,500,000 Shares Common Stock We are offering 12,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “GH.” The last reported sale price of our common stock on the Nasdaq Global Select Market on May 22

You’ve Exceeded the SEC’s Traffic Limit

EX-FILING FEES Exhibit 107 Ex – Filing Fees Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) GUARDANT HEALTH, INC.

Filing Fee Table

EX-FILING FEES 6 d494939dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Ag

Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of U.S. Bank Trust Company, National Association, as trustee under the indenture filed as Exhibit 4.2 above.

EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036

Form of Indenture.

EX-4.2 Exhibit 4.2 GUARDANT HEALTH, INC. INDENTURE Dated as of , 20 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section

Subject to Completion Preliminary Prospectus Supplement dated May 22, 2023

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Powers of Attorney (incorporated by reference to the signature page hereto).

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 22, 2023 Registration No.

Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield

EX-99.1 Exhibit 99.1 Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test Shield™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening modalities PALO ALTO, Calif., May 9, 2023 — Guardant Health,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (

Guardant Health Reports First Quarter 2023 Financial Results Q1 revenue increased 34% year over year driven by clinical volume growth of 45% Raises 2023 revenue guidance to $535 to $545 million

Guardant Health Reports First Quarter 2023 Financial Results Q1 revenue increased 34% year over year driven by clinical volume growth of 45% Raises 2023 revenue guidance to $535 to $545 million PALO ALTO, Calif.

Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Announces Additions to Leadership Team • Ines Dahne-Steuber named as chief operating officer • Darya Chudova promoted to chief technology officer

EX-99.1 Exhibit 99.1 Guardant Health Announces Additions to Leadership Team • Ines Dahne-Steuber named as chief operating officer • Darya Chudova promoted to chief technology officer PALO ALTO, Calif. – May 8, 2023 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief operati

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( as permitted b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Letter of Ernst & Young LLP, dated April 10, 2023

1

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.

As filed with the Securities and Exchange Commission on March 2, 2023

S-8 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No.

Musa Tariq joins Guardant Health board of directors

EX-99.1 Exhibit 99.1 PRESS RELEASE Musa Tariq joins Guardant Health board of directors PALO ALTO, Calif., February 27, 2023 — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a dis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 GUARDANT HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 GUARDANT HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

List of Subsidiaries

Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington Morpheus Merger Sub, Inc. Delaware Guardant Health Screening Corp. Delaware Guardant Health International, Inc. Delaware Guarda

Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook Q4 clinical and biopharma volumes up 41% and 24% year over year

Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook Q4 clinical and biopharma volumes up 41% and 24% year over year PALO ALTO, Calif.

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

GH / Guardant Health Inc / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment

SC 13G/A 1 brhc10047902sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) Guardant Health, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (

GH / Guardant Health Inc / Capital International Investors - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

GH / Guardant Health Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

GH / Guardant Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01022-guardanthealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Guardant Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 40131M109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to desig

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results Full year clinical and biopharma volumes up 42% and 40% year over year

EX-99.1 2 gh-192023xexhibit991.htm EX-99.1 Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results Full year clinical and biopharma volumes up 42% and 40% year over year PALO ALTO, Calif. January 9, 2023 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets a

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizatio

1

Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer •The test demonstrated 83% sensitivity for the detection of colorectal cancer with specificity of 90% •Results pave the way for first potential FDA-approved and Medicare-reimbursed blood test for colorectal cancer screening •The company will host a webcast and conference call to discuss the results today at 5:00 p.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

Guardant Health Reports Third Quarter 2022 Financial Results Q3 clinical and biopharma volumes up 42% and 40% year over year

Guardant Health Reports Third Quarter 2022 Financial Results Q3 clinical and biopharma volumes up 42% and 40% year over year PALO ALTO, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Reports Second Quarter 2022 Financial Results Q2 clinical and biopharma volumes up 40% and 65% year over year

Guardant Health Reports Second Quarter 2022 Financial Results Q2 clinical and biopharma volumes up 40% and 65% year over year PALO ALTO, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Steve E. Krognes Joins Guardant Health Board of Directors

Exhibit 99.1 Steve E. Krognes Joins Guardant Health Board of Directors PALO ALTO, Calif. July 7, 2022 ? Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Steve E. Krognes to its board of directors. Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Ther

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture

Exhibit 99.1 PRESS RELEASE Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture PALO ALTO, Calif. June 13, 2022 ? Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc. held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Mi

Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (

Guardant Health Reports First Quarter 2022 Financial Results Q1 clinical and biopharma volumes up 47% and 45% year over year

Guardant Health Reports First Quarter 2022 Financial Results Q1 clinical and biopharma volumes up 47% and 45% year over year PALO ALTO, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 d345708ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

As filed with the Securities and Exchange Commission on February 28, 2022

As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

List of Subsidiaries

Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington

Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook Q4 clinical and biopharma volumes up 48% and 36% year over year

Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook Q4 clinical and biopharma volumes up 48% and 36% year over year REDWOOD CITY, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

GH / Guardant Health Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

GH / Guardant Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Guardant Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 40131M109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

GH / Guardant Health Inc / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Guardant Health, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 40131M109 (CUSIP Number) January

Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation

Exhibit 99.1 Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation REDWOOD CITY, Calif. January 7, 2022 ? Guardant Health, Inc. (Nasdaq: GH) today announced that it has reached an agreement to settle all pending litigation concerning the company?s digital sequencing technology patents with Foundation Medicine, Inc. Pursuant to the settlement agreement

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

Guardant Health Reports Third Quarter 2021 Financial Results Achieved record revenue of $94.8 million Growth of 35% and 58% year over year in clinical and biopharma volumes, respectively

Guardant Health Reports Third Quarter 2021 Financial Results Achieved record revenue of $94.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Appoints Myrtle Potter to its Board of Directors

Exhibit 99.1 PRESS RELEASE Guardant Health Appoints Myrtle Potter to its Board of Directors REDWOOD CITY, Calif.? October 20, 2021 (BUSINESS WIRE) ? Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors. ?We are very pleased to welcome Myrtle Potter to our Board of Directors as we continue to build and deliver on ou

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 15, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors

Exhibit 99.1 PRESS RELEASE Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors REDWOOD CITY, Calif.? August 5, 2021 (BUSINESS WIRE) ? Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced a new leadership structure to support the Company?s strategic objectives for future growth. Under this stru

Guardant Health Reports Second Quarter 2021 Financial Results Achieved revenue of $92.1 million, driven by 52% year over year growth in clinical volume

Guardant Health Reports Second Quarter 2021 Financial Results Achieved revenue of $92.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 (August 4, 2021) GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporatio

GH / Guardant Health Inc / SOFTBANK VISION FUND (AIV M1) L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) SB Investment Advisers (UK) Limited 69 Grosvenor St Mayfair, London W1K 3JP Attn: Brian Wheeler (Name, Address and Telephone Number of Person Auth

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Reports First Quarter 2021 Financial Results Achieved revenue of $78.7 million, driven by approximately 18,400 clinical tests

Guardant Health Reports First Quarter 2021 Financial Results Achieved revenue of $78.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) SB Inv

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) SB Investment Advisers (UK) Limited 69 Grosvenor St Mayfair, London W1K 3JP Attn: Brian Wheeler (Name, Address and Telephone Number of Pe

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

File No. 333-253733

As filed with the Securities and Exchange Commission on March 1, 2021 Registration No.

Forms of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan

EXHIBIT 10.3(d) Founder PSU Award Agreement GUARDANT HEALTH, INC. 2018 INCENTIVE AWARD PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT NOTICE (FOUNDERS) Guardant Health, Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the performance-based Restricted Stock Units (the ?PSUs?) described in this Performance-Based Restricted Stock Unit Grant

Amendment #5 to Supply Agreement, dated January 1, 2021, by and between the Registrant and Illumina, Inc.

EXHIBIT 10.19 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. AMENDMENT #5 TO SUPPLY AGREEMENT Illumina, Inc., a Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA 92122 ("Illumina") and Guardant Health, Inc.,

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

List of Subsidiaries

Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021 2020 Revenue Increased 34% Over Prior Year Period

Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021 2020 Revenue Increased 34% Over Prior Year Period REDWOOD CITY, Calif.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Guardant Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 40131M109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Ru

Safe Harbor Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the “Company”)’s

EX-99.1 Exhibit 99.1 J.P. Morgan Healthcare Conference January 11, 2021Exhibit 99.1 J.P. Morgan Healthcare Conference January 11, 2021 Safe Harbor Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the “Company”)’s future results

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of class of securities) (CUSIP number) Januar

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of class of securities) 40131M109 (CUSIP number) January 1, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 1, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizatio

Offer Letter, dated December 4, 2020, by and between Guardant Health, Inc. and Michael Bell

EX-10.1 Exhibit 10.1 GUARDANT HEALTH 505 Penobscot Drive, Redwood City, CA 94063 USA / 855.698.8887 client services / www.guardanthealth.com REVISED OFFER LETTER December 4, 2020 Michael Bell 61 Van Tassel Lane Orinda, CA 94563 Dear Mike, On behalf of Guardant Health, Inc. (the “Company”), I am pleased to offer you the position of Chief Financial Officer working as part of our Finance Department i

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Employment Letter, dated December 7, 2020, by and between Guardant Health, Inc. and Derek Bertocci

EX-10.2 Exhibit 10.2 GUARDANT HEALTH 505 Penobscot Drive, Redwood City, CA 94063 USA / 855.698.8887 client services / www.guardanthealth.com December 7, 2020 CONFIDENTIAL Derek Bertocci 240 San Mateo Ave Los Gatos, CA 95030 Re: Employment Offer Dear Derek: This letter will provide details regarding your continued employment with Guardant Health, Inc. (the “Company”) effective as of December 7, 202

Guardant Health Names Michael Bell as New Chief Financial Officer

EX-99.1 Exhibit 99.1 PRESS RELEASE Guardant Health Names Michael Bell as New Chief Financial Officer REDWOOD CITY, Calif. December 11, 2020 (BUSINESS WIRE) — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Michael will succeed Derek Bertocci who has retired after successfu

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Form of Capped Call Confirmation

EX-10.1 Exhibit 10.1 [Dealer Address] To: Guardant Health, Inc. 505 Penobscot Dr. Redwood City, California 94063 From: [Dealer] Re: [Base] [Additional] Capped Call Transaction Ref. No: [ ] Date: [November 16, 2020][November 18, 2020] Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entere

Indenture, dated as of November 19, 2020, between Guardant Health, Inc. and U.S. Bank National Association, as trustee

EX-4.1 Exhibit 4.1 EXECUTION VERSION GUARDANT HEALTH, INC. and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of November 19, 2020 0% Convertible Senior Notes due 2027 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 13 Article 2. The Notes 14 Section 2.01. Form, D

Guardant Health, Inc. Announces Proposed Convertible Senior Notes Offering

Exhibit 99.1 Guardant Health, Inc. Announces Proposed Convertible Senior Notes Offering Redwood City, California?(BUSINESS WIRE)?Nov. 16, 2020?Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the ?notes?) in a private offering to qualified institutional

Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering

Exhibit 99.2 Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering Redwood City, California?(BUSINESS WIRE)?November 16, 2020?Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due 2027 (the ?notes?) in a private offering to qualified institutional buyers pursuant to Rule 144

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat

Sublease Agreement, dated July 31, 2020, by and between Guardant Health, Inc. and 3000 Hanover, LLC

SUBLEASE BY AND BETWEEN 3000 Hanover, LLC, a Delaware limited liability company as Landlord and Guardant Health, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Reports Third Quarter 2020 Financial Results Q3 2020 Revenue Increase of 23% Over Prior Year Period

Guardant Health Reports Third Quarter 2020 Financial Results Q3 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif.

GH / Guardant Health, Inc. / SOFTBANK VISION FUND (AIV M1) L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) SB Investment Advisers (UK) Limited 69 Grosvenor St Mayfair, London W1K 3JP Attn: Brian Wheeler (Name, Address and Telephone Number of Pe

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizatio

Underwriting Agreement, dated as of October 6, 2020, by and among Guardant Health, Inc., SVF Bluebird (Cayman) Limited, and J.P. Morgan Securities LLC (incorporated by reference to Exhibit 1.1 of the Company’s current report on Form 8-K filed October 13, 2020).

Exhibit 1.1 Execution Version GUARDANT HEALTH, INC. 7,000,000 Shares of Common Stock, par value $0.00001 per share Underwriting Agreement October 6, 2020 J.P. Morgan Securities LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Certain stockholders named in Schedule 2 hereto

CALCULATION OF REGISTRATION FEE

Filed Pursuant to Rule 424(b)(7) Registration No. 333-236806 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.00001 par value per share 7,700,000 $ 102.00 $ 785,400,000 $ 85,688 (1)Includes 700,000 shares of common stock that the underw

Subject to Completion Preliminary Prospectus Supplement dated October 6, 2020

Filed Pursuant to Rule 424(b)(7) Registration No. 333-236806 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to s

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organiz

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization

Non-Employee Director Compensation Program, effective as of June 12, 2020

Exhibit 10.1 GUARDANT HEALTH, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (EFFECTIVE JUNE 12, 2020) In order to further align directors’ interests with those of long-term stockholders, on June 12, 2020 the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) approved a number of modifications to its Non-Employee Director Compensation Program (this “Program”). Specifically,

Guardant Health Reports Second Quarter 2020 Financial Results Q2 2020 Revenue Increase of 23% Over Prior Year Period

Guardant Health Reports Second Quarter 2020 Financial Results Q2 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Appoints Vijaya Gadde to its Board of Directors

Exhibit 99.1 Guardant Health Appoints Vijaya Gadde to its Board of Directors REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Vijaya Gadde to serve on its Board of Directors. “We’re delighted to welcome Vijaya to our Board of Directors. Vijaya is an outstanding addition to our Board and a proven business

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Exhibit 99.1

Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons below agree to the joint filing on behalf of each of them of the Schedule 13D to which this Agreement is an exhibit (and any further amendment filed by them) with respect to the shares of Common Stock of Guardant Health, Inc. This agre

Exhibit 99.2

Exhibit 99.2 FORM OF LOCK-UP AGREEMENT June 1, 2020 J.P. MORGAN SECURITIES LLC As Representative of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 Re: Guardant Health, Inc. —Public Offering Ladies and Gentlemen: The undersigned understands that you, as representative (the “Representa

GH / Guardant Health, Inc. / Softbank Vision Fund (aiv M1) L.p. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Exhibit 99.3

Exhibit 1.1 GUARDANT HEALTH, INC. 11,500,000 Shares of Common Stock, par value $0.00001 per share Underwriting Agreement June 1, 2020 J.P. Morgan Securities LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Guardant Health, Inc., a Delaware corporation (the “Company”), propo

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.00001 par value per share 13,225,000

Filed Pursuant to Rule 424(b)(5) Registration No. 333-236806 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.00001 par value per share 13,225,000 $ 84.00 $ 1,110,900,000 $ 144,195 (1) Includes 1,725,000 shares of common stock that the

Subject to Completion Preliminary Prospectus Supplement dated June 1, 2020

Filed Pursuant to Rule 424(b)(5) Registration No. 333-236806 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to s

Form of Waiver Letter Agreement

Exhibit 10.2 May 26, 2020 Re: Waiver of Compensation Dear [Helmy / AmirAli]: This letter serves to memorialize your agreement with Guardant Health, Inc. (the “Company”) regarding certain compensation-related matters during the Waiver Period (as defined below). Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Company’s Executive Severance Plan, as amen

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Form of Performance-Based Restricted Stock Unit Agreement

Exhibit 10.1 GUARDANT HEALTH, INC. 2018 INCENTIVE AWARD PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT NOTICE (FOUNDERS) Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the performance-based Restricted Stock Units (the “PSUs”) described in this Performance-Based Restricted Stock Unit Grant Notice (Founders) (this “Grant

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.

Guardant Health Reports First Quarter 2020 Financial Results Q1 2020 Revenue Increase of 84% Over Prior Year Period

EX-99.1 2 gh-03312020xexhibit991.htm EXHIBIT 99.1 Guardant Health Reports First Quarter 2020 Financial Results Q1 2020 Revenue Increase of 84% Over Prior Year Period REDWOOD CITY, Calif. May 7, 2020 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics,

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2020 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)

Description of Registrant’s Securities Registered under Section 12 of the Exchange Act

Exhibit 4.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Except as otherwise indicated herein or as the context otherwise requires, references in this exhibit to “we,” “us,” “our” and “our company” refer to Guardant Health, Inc. The following description of our common stock and certain provisions of our amended and restated cer

File No. 333-236807

As filed with the Securities and Exchange Commission on March 2, 2020 Registration No.

List of Subsidiaries

Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington